Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.65 |
| ▸ | MTOR | P42345 | 20/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL53928 | 0.92 | PIK3CA (0.56) | PIK3CAMTORPIK3CG | |
| SCHEMBL3989253 | 0.90 | PIK3CA (0.67) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL3984983 | 0.88 | PIK3CA (0.74) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL55590 | 0.85 | PIK3CA (0.75) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL23157345 | 0.83 | PIK3CA (0.54) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL3986971 | 0.82 | PIK3CA (0.57) | PIK3CAMTORPIK3CG | |
| SCHEMBL60353 | 0.82 | PIK3CA (0.56) | PIK3CAMTORPIK3CG | |
| SCHEMBL3655411 | 0.81 | PIK3CA (0.85) | PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL54844 | 0.81 | PIK3CA (0.82) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL54855 | 0.80 | PIK3CA (0.88) | PIK3CAMTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2212333-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885AURKB 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.